Genprex, Inc. (NASDAQ:GNPX) Short Interest Update

Genprex, Inc. (NASDAQ:GNPX) was the recipient of a significant increase in short interest in February. As of February 15th, there was short interest totalling 1,130,000 shares, an increase of 505.2% from the January 31st total of 186,700 shares. Based on an average daily trading volume, of 920,700 shares, the days-to-cover ratio is currently 1.2 days. Approximately 13.7% of the company’s stock are sold short.

Hedge Funds Weigh In On Genprex

A hedge fund recently raised its stake in Genprex stock. Virtu Financial LLC lifted its holdings in Genprex, Inc. (NASDAQ:GNPX) by 64.1% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 80,424 shares of the company’s stock after acquiring an additional 31,400 shares during the period. Virtu Financial LLC owned approximately 0.95% of Genprex worth $68,000 as of its most recent filing with the SEC. Institutional investors own 14.05% of the company’s stock.

Genprex Trading Down 1.3 %

NASDAQ:GNPX traded down $0.01 on Thursday, hitting $0.38. 615,948 shares of the company’s stock were exchanged, compared to its average volume of 1,032,345. The firm has a 50-day moving average price of $0.66 and a 200-day moving average price of $0.86. Genprex has a 52 week low of $0.28 and a 52 week high of $5.41.

Genprex Company Profile

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.